Esophagogastric Junction Cancer clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
open to eligible people ages 18 years and up
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
at UCSD
Our lead scientists for Esophagogastric Junction Cancer research studies include Sandip Patel, MD.
Last updated: